Laurus Labs Q1 FY27: Revenue up 29% YoY, PAT jumps 125% YoY

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

LAURUSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹1570.00

prior close

₹1578.10

announcement price

In-mkt

timing

Nifty Midcap 150market-0.1%+2.4% vs market

Pharmaceuticals peers, median of 164sector-0.1%+2.4% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Midcap 150 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+1.0

15m

+1.0

30m

+1.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3-0.1+2.4-0.1+2.4

Next day

+9.0+1.0+8.0+0.5+8.5

+11.8+1.0+10.8+0.0+11.8

+13.4+1.8+11.5+0.6+12.8

+13.5+1.4+12.0-0.1+13.6

+15.6+1.9+13.7+0.2+15.5

+17.2+2.8+14.4+0.8+16.4

15d

+13.8+3.1+10.7+2.7+11.2

+14.5+3.2+11.4+1.4+13.2

+29.0-1.0+30.0+3.6+25.4

+31.1-8.3+39.5-4.2+35.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Laurus Labs posted strong Q1 FY27 results. Consolidated revenue from operations rose 29 percent YoY to Rs 2,026 crores versus Rs 1,570 crores in Q1 FY26. Net profit after tax jumped 125 percent YoY to Rs 362 crores versus Rs 161 crores. Standalone revenue grew 23 percent to Rs 1,757 crores and PAT rose 84 percent to Rs 290 crores. Consolidated EPS stood at Rs 6.81 versus Rs 3.02. EBITDA margin expanded sharply on better operating leverage. Auditor Deloitte Haskins and Sells LLP issued an unmodified limited review report.

Likely market impact

Beats expectations with sharp margin expansion and over 2x PAT growth, signalling robust business momentum for shareholders.